{Reference Type}: Systematic Review
{Title}: Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis.
{Author}: Luzarraga Aznar A;Bebia V;Gomez-Hidalgo NR;López-Gil C;Miguez M;Colas E;Pérez-Benavente A;Gil-Moreno A;Cabrera S;
{Journal}: Clin Transl Oncol
{Volume}: 26
{Issue}: 7
{Year}: 2024 Jul 5
{Factor}: 3.34
{DOI}: 10.1007/s12094-024-03401-y
{Abstract}: <B>OBJECTIVE: </B>Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.<BR><B>METHODS: </B>A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.<BR><B>RESULTS: </B>Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).<BR><B>CONCLUSIONS: </B>The presence of LNM seems to be influenced by molecular classification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.